Introduction
============

Colorectal cancer (CRC) continues to be the third most commonly diagnosed cancer, after lung and breast cancer, and the fourth most common cause of cancer death worldwide, albeit with a declining incidence and mortality rate in countries with programmatic screening.[@b1-ott-9-4833] In Western countries, CRC is the leading cause of cancer morbidity and mortality, while in developed countries CRC incidence is higher, and accounts for an even higher proportion of cancer deaths.[@b2-ott-9-4833] Early diagnosis of CRC is very important for improving treatment outcomes; however, most patients already have localized disease at diagnosis, and hence cannot receive curative (R0) surgical resection. Considering that inhibitors of vascular endothelial growth factor and epidermal growth factor receptor have limited activity in monotherapy, chemotherapy remains the primary therapeutic option for these patients with unresectable metastatic CRC (mCRC). Combination therapy is now the predominant approach in cancer chemotherapy. The two most commonly used cytotoxic combinations for unresectable mCRC are infused 5-fluorouracil (FU) (plus leucovorin \[LV\]), with irinotecan (CPT-11) (FOLFIRI) and infused FU (plus LV) with oxaliplatin (LOHP) (FOLFOX), with or without (±) bevacizumab. The comparisons of FOLFOX with FOLFIRI in randomized studies have reported equivalent activity and efficacy.[@b3-ott-9-4833] The most widely used triplet combination includes CPT-11, FU/LV, and LOHP ± bevacizumab. A study suggested that this combination is associated with promising survival, when unresectable mCRC patients are exposed to all the three most active agents, irrespective of their sequence.[@b3-ott-9-4833] In addition, a pooled analysis of seven Phase III trials demonstrated that survival has relationship with the proportion of patients who receive all the three active drugs but not with the proportion of patients who receive any second-line therapy.[@b4-ott-9-4833] This analysis also showed that only 50%--80% of patients can be exposed to all the three drugs in a sequential strategy with two-drug combinations. Whether FOLFOXIRI ± bevacizumab combination is better or not than FOLFIRI ± bevacizumab combination as first-line treatment for the unresectable mCRC patients is not completely known. So, we performed this first meta-analysis to compare the survival benefit and safety between the combinations of FOLFOXIRI ± bevacizumab and FOLFIRI ± bevacizumab.

Materials and methods
=====================

Study search strategy
---------------------

We performed a systematic assessment according to Preferred Reporting Items for Systematic Reviews and Meta-analysis criteria.[@b5-ott-9-4833] We searched PubMed, EMBASE, and the annual meeting abstracts of the American Society of Clinical Oncology (from 1985 to December 2015) for original articles. We searched all published (full papers or abstracts in English language) and unpublished trials that compared FOLFOXIRI ± bevacizumab (experimental group) with FOLFIRI ± bevacizumab (control group) for the treatment of colorectal cancer (before December 2015). To minimize the risk of selection or information bias, only prospective studies were included in our assessment. We searched articles with various combinations of different terms: "fluorouracil, oxaliplatin, irinotecan", "fluorouracil, irinotecan", "unresectable", "advanced", "metastatic", "first-line treatment", "randomized controlled trial", "colorectal cancer", "colon cancer", "rectal cancer", and others. The reference lists of relevant studies were also reviewed to avoid missing potential studies.

Selection of trials
-------------------

To be eligible for our analysis, the trials had to meet the following criteria: 1) subjects were patients with unresectable mCRC, with histological or cytological confirmation; 2) prospective Phase II and III randomized controlled trials (RCTs); 3) control arm patients received FOLFIRI or FOLFIRI + bevacizumab (collectively referred to as the FOLFIRI group), and experimental arm patients received FOLFOXIRI or FOLFOXIRI + bevacizumab (collectively referred to as the FOLFOXIRI group) as first-line treatment; and 4) control arm and experimental arm were compared without confounding by additional agents or interventions (ie, in the combination chemotherapy, the control and experimental arms had to differ only with respect to addition or lack of LOHP component).

Two independent reviewers (WX and MK) assessed all the identified abstracts according to the predefined inclusion criteria. If only one reviewer considered an abstract eligible, the full text of the article was retrieved, and both reviewers reviewed it in detail. All publications were included, but only the most recent and the most informative data were used.

Quality assessment
------------------

The quantitative five-point Jadad score was used to assess the quality of included trials based on the report of the methods and results of the studies.[@b6-ott-9-4833]

Data extraction
---------------

To avoid bias in the data extraction process, two reviewers (WX and MK) independently extracted the data from the trials and compared the results. The following information was extracted: 1) publication details such as first author, year of publication, country, phase of study, and form of publication (full/abstract); 2) information of treatment such as chemotherapy regimens, treatment line, median overall survival (OS), median progression-free survival (PFS), overall response rate (ORR), toxicity, and R0 secondary resection rate; and 3) characteristics of patients such as number of patients, age, sex, prior chemotherapy history, and Eastern Cooperative Oncology Group performance status (PS). Before performing the analyses, the extracted data of each published study were carefully double-checked by another reviewer (YG). Any discrepancies were resolved by group discussion or by contacting the authors of the original study. If multiple publications of the same trial were retrieved, or if there were data inconsistencies between publications of the same trial, all publications were included, but only the most recent and the most informative data were used.

Statistical analysis
--------------------

The primary outcome measure was OS, which was defined as time from random assignment to death. Secondary outcome measures were PFS -- defined as the time between date of random assignment and date of progression, or date of death for patients without progression, or last date of follow-up for censored patients -- and ORR -- defined as the sum of partial and complete response rates. A hazard ratio (HR) was calculated to assess the survival advantage of the experimental group as compared with the control group. Odds ratios (ORs) were calculated to assess objective response rate and toxic events. For safety profile, data on grade 3--4 adverse events were extracted and analyzed. Between-study heterogeneity was estimated by *χ*^2^-based *Q* test.[@b7-ott-9-4833] Heterogeneity was considered statistically significant when *P* heterogeneity was ≤0.1 or *I*^2^ was \>50%, or both. We applied a random-effects model; a fixed-effects model was used when there is lack of significant heterogeneity. The presence of publication and selection bias was evaluated through funnel plots using the Begg's and Egger's tests.[@b8-ott-9-4833],[@b9-ott-9-4833] All statistical analyses were performed using the STATA version 10.0 software (StataCorp LP, College Station, TX, USA).

All reported *P*-values were from two-sided versions of the respective tests. A *P*-value \<0.05 was considered statistically significant. All confidence intervals (CIs) had two-sided probability coverage of 95%.

Results
=======

Characteristics of included trials
----------------------------------

Six full-text articles[@b10-ott-9-4833]--[@b15-ott-9-4833] were included in this meta-analysis; three of these articles were updated trials.[@b10-ott-9-4833],[@b13-ott-9-4833],[@b15-ott-9-4833] The flow chart of inclusion and exclusion of studies is shown in [Figure 1](#f1-ott-9-4833){ref-type="fig"}. There were 1,035 patients included in this assessment, of which 511 were randomly assigned to receive chemotherapy with FOLFOXIRI ± bevacizumab and 524 were randomly assigned to receive chemotherapy with FOLFIRI ± bevacizumab. The characteristics of the three included trials are summarized in [Table 1](#t1-ott-9-4833){ref-type="table"}.

Efficacy
--------

Data on OS were available for three trials (1,035 patients; [Table 2](#t2-ott-9-4833){ref-type="table"}). There was a statistically significant association with 16% reduction in the hazard of death in the FOLFOXIRI ± bevacizumab arm, as compared with FOLFIRI ± bevacizumab arm (HR, 0.84; 95% CI, 0.73--0.97; *P*=0.016; [Figure 2](#f2-ott-9-4833){ref-type="fig"}). Data on PFS were available for two trials (752 patients; [Table 2](#t2-ott-9-4833){ref-type="table"}). The experimental group was also associated clinically with a 31% reduction in the hazard of death as compared with the control group; there was a significant improvement in the PFS (HR, 0.69; 95% CI, 0.59--0.81; *P*\<0.0001; [Figure 3](#f3-ott-9-4833){ref-type="fig"}). ORR was stated in three trials, which included 1,035 patients ([Table 2](#t2-ott-9-4833){ref-type="table"}). The experimental group was characterized by a significant 96% increase in the OR of response in comparison with the control group (OR, 1.96; 95% CI, 1.28--2.98; *P*=0.002; [Figure 4](#f4-ott-9-4833){ref-type="fig"}). There was no statistically significant heterogeneity in the HR of both OS and PFS from the trials, and fixed-effects model was applied. Nevertheless, there was statistically significant heterogeneity in the OR of ORR, so a random-effects model was applied. In addition, there was no statistically significant improvement in radical resection of metastases in the experimental group compared to the control group in two trials; only Falcone et al's trial reported a statistically significant improvement (*P*=0.033).[@b11-ott-9-4833] We did not perform heterogeneity analysis due to of the lack of details. A summary of grade 3--4 adverse effects is reported in [Table 3](#t3-ott-9-4833){ref-type="table"}. With regard to the incidence of thrombocytopenia, febrile neutropenia, nausea/vomiting, and asthenia, no significant difference in any adverse event was observed between the experimental group and the control group. In addition, the incidence of each mentioned significant adverse effect was much lower than 6.3% in the control group. In contrast, the experimental group was characterized by a significantly higher incidence of neutropenia, anemia, diarrhea, stomatitis, and neuropathy (OR, 2.45, 4.92, 2.25, 1.96, and 18.64, respectively). Nevertheless, the incidence of each mentioned significant adverse effect was much lower than 35%. In addition, no significant difference was observed with regard to treatment-related death. Heterogeneity existed for some adverse effects among trials, possibly due to the different combinations and doses used.

Publication bias
----------------

We constructed Begg's funnel plot and performed Egger's test to assess the publication bias in the literature. The shapes of the funnel plots indicated the absence of publication bias ([Figure 5](#f5-ott-9-4833){ref-type="fig"}). Furthermore, Egger's test was used to statistically confirm the symmetry of the funnel plots. The results also did not suggest any evidence of publication bias.

Discussion
==========

Many studies reported the feasibility of the combination of FOLFOXIRI ± bevacizumab.[@b16-ott-9-4833]--[@b18-ott-9-4833] In addition, some studies suggested that FOLFOXIRI ± bevacizumab was more efficient compared to FOLFIRI ± bevacizumab as first-line treatment for unresectable mCRC. However, some studies showed contrasting results. Our overall analysis indicated that experimental group showed significant improvement in OS and PFS in comparison with the control group. Our data on ORR reinforced further the survival result due to of a higher response rate in the experimental group. In addition, there was an improvement in radical resection of metastases in the experimental group, but statistically significant difference was undefined due to the limited published data. Considering safety profile, there was no significant difference between the two groups with respect to all grade 3--4 adverse events except neutropenia, anemia, diarrhea, stomatitis, and neuropathy. However, the incidence rate of anemia, stomatitis, and neuropathy was low in both arms. Conversely, the incidence rate of other adverse events was high in the experimental group, but they were predictable, manageable, and acceptable, compared to the control group. With regard to treatment-related death, no significant difference was observed between the two groups. The experimental group was associated with a longer OS and PFS, a higher response rate, and almost equivalent safety compared with the control group. All trials provided data on OS, and we extracted updated results from the published articles via PubMed. The results of all trials[@b10-ott-9-4833],[@b13-ott-9-4833],[@b15-ott-9-4833] showed that OS was prolonged in patients with unresectable mCRC in the experimental group, regardless of there being no significant difference in OS in one trial (Souglakos et al's trial[@b14-ott-9-4833]). The median OS of patients assigned to FOLFOXIRI ± bevacizumab arm was significantly longer than that of patients assigned to FOLFIRI ± bevacizumab arm in all trials except Souglakos et al's trial. Meanwhile, the forest plot of OS showed favorable results for the experimental group compared with the control group in all included trials except Souglakos et al's trial. Souglakos et al's trial reported that updated median OS was 21.9 months in the experimental group compared with 19.9 months in the control group (HR, 1.08; 95% CI, 0.8--1.45; *P*=0.41).[@b15-ott-9-4833] In spite of this, statistically significant difference in OS in favor of the experimental group was still observed in our meta-analysis. In view of long survival benefit, FOLFOXIRI ± bevacizumab could be an optimal choice of treatment for patients with unresectable mCRC under the premise of reasonable selection of target population, including those who have never ever received adjuvant chemotherapy and who had a PS of 0--1. All trials[@b11-ott-9-4833],[@b12-ott-9-4833],[@b14-ott-9-4833] reported that the response rate in the experimental group was significantly higher than that in the control group except Souglakos et al's trial[@b15-ott-9-4833] (43% versus 33.6% in each group; *P*=0.11). The ORRs were 58.1% in the experimental group and 43.1% in the control group in this analysis, which demonstrated a 96% increase in the OR of response in the experimental group than that in the control group, and the difference was significant (*P*=0.002). Data on PFS were available in two trials,[@b12-ott-9-4833],[@b13-ott-9-4833] and significant difference was observed in PFS in our meta-analysis ([Figure 4](#f4-ott-9-4833){ref-type="fig"}). The PFS benefit of the combination of FOLFOXIRI ± bevacizumab should be further investigated in more trials.

In addition, the following issues may confound the assessment of survival and response rate, and they are worthy of further discussion. First, the different median age and the proportion of patients, the patients older than 65 years, and those with an Eastern Cooperative Oncology Group PS of 0--1 were higher in Souglakos et al's trial in comparison with that reported in the other trials. In addition, the study enrolled patients \>75 years old, which was relatively unusual compared with the previous randomized studies.[@b3-ott-9-4833],[@b19-ott-9-4833] However, Souglakos et al's trial and some other trials[@b18-ott-9-4833],[@b20-ott-9-4833] revealed that age alone is not a negative predictor of the efficacy and the tolerance of currently used chemotherapy regimens, but the PS status and response to treatment are also independent prognostic factors of survival. Second, inconsistency in systemic therapy before and after the study among the three trials may affect the end points. Loupakis et al's study[@b12-ott-9-4833] suggested that patients who have received adjuvant chemotherapy are not ideal candidates for an intensified upfront chemotherapy. From Souglakos et al's trial, we found that adjuvant chemotherapy is not a significant factor of the patients' outcome, while Falcone et al's study[@b11-ott-9-4833] did not refer to adjuvant chemotherapy. The details could not be searched from the articles, and we got no updated information from the authors.

The findings of our study showed that almost equivalent tolerance was observed among the two treatment groups except significant increases in grade 3--4 neutropenia, anemia, diarrhea, stomatitis, and neuropathy in the experimental group. However, all toxicities including those mentioned were tolerable, predictable, and manageable. Treatment-related death, which was an important toxic indicator, was reported in all trials. Two trials reported that more than one person died in each group.[@b12-ott-9-4833],[@b14-ott-9-4833] Loupakis et al's trial reported six and four persons died in each group, respectively. Souglakos et al's trial reported two and two persons died in each group, respectively. In total, due to of the limited published data, significant difference in treatment-related death was undefined in our meta-analysis.

The pharmacokinetic data demonstrated that the dose of drugs used for the two groups was appropriate. In the chemotherapy regimens of Souglakos et al's trial, the FU bolus was maintained, so the use of a dose of LOHP and CPT-11 significantly lower than in the other trials.

This meta-analysis presents the most systematic comparison of the efficiency and the safety between the experimental group and the control group on the basis of all relevant RCTs. All chosen articles were of high quality, in order to enhance the reliability of our analyses and reduce the inherent bias. However, limitations of these studies also need our attention. First, to our knowledge, the quality of the individual studies has an effect on the results of any meta-analysis. Although all trials were RCTs and we extracted information from the updated trials, no updated or confirmed results could be obtained from the authors. Therefore, our results should be interpreted with care. Second, our meta-analysis was based on abstracted data and not on individual patient data. Meta-analyses based on individual patient data tend to give a more robust estimation of the association compared with published data analyses. Third, the difference in treatment schedules among the trials (data not shown) might have resulted in increase in the clinical heterogeneity of the meta-analysis. Finally, lack of blinding, which is inevitable in any included studies, might have contributed to an overestimate of the treatment effects. Because the two treatment methods studied were very different (triple drug ± bevacizumab versus double drug ± bevacizumab), the treatment allocation could not be concealed from the investigators or patients.

In our meta-analysis, there remain some problems which should be illustrated and solved through further prospective trials. Firstly, to our knowledge, chemotherapy treatment combination molecular-targeted agents are more promising, which have been widely applied in the clinical treatment. However, two trials in our meta-analysis were conducted before the inclusion of monoclonal antibodies to standard of care, and thus, they were not optimized to present practice. Secondly, to our knowledge, the liver is the most common site of metastasis in patients with colorectal cancer. Treatment strategies that allow hepatic resection as part of an interdisciplinary consensus offer higher 5-year survival rates than palliative treatment alone.[@b21-ott-9-4833] The trial by Loupakis et al did not focus on converting patients with liver metastases into candidates for surgical resection. The other trials performed higher rate of R0 metastatic surgery assessing the role of intensified therapy toward that goal. However, the proportion of patients with metastasis limited to the liver was very low. Thus, we are unable to make any conclusion regarding the benefit of treatment with FOLFOXIRI ± bevacizumab or FOLFIRI ± bevacizumab in these patients. Recently, the OLIVIA trial[@b22-ott-9-4833] compared FOLFOXIRI + bevacizumab with FOLFOX-6 (FU, LV, and LOHP) + bevacizumab in mCRC patients with liver-limited metastasis. The trial found that FOLFOXIRI plus bevacizumab improved PFS and the secondary resection of metastases, but it did not mention the statistically significant difference. These problems need to be solved by further prospective trials.

Our meta-analysis indicates that triple-drug treatment is a good strategy to optimize the feasibility and efficacy of subsequent treatments. It also gives full answer to the question of whether the upfront use of FOLFOXIRI improves survival compared with the sequential use of LOHP and CPT-11.

In summary, FOLFOXIRI ± bevacizumab chemotherapy was not only superior to FOLFIRI ± bevacizumab chemotherapy in terms of OS and PFS but also led to increased responses. All of these results confirmed that FOLFOXIRI ± bevacizumab showed almost equivalent tolerance and much more effectiveness compared to FOLFIRI ± bevacizumab. Thus, this combination should be considered as a first-line treatment option for the patients with unresectable colorectal cancer under the premise of reasonable selection of target population and combination of chemotherapy drugs. The superiority of the FOLFOXIRI ± bevacizumab therapy compared to the other double-drug combinations needs to be further evaluated and confirmed through larger studies with longer observation period.

This study was supported by a grant from The Project of Plans for the Development of Science and Technology of Nanjing, China (Grant No 201208020).

**Disclosure**

The authors declare no conflict of interest in this work.

![Flow chart of inclusion and exclusion of trials.\
**Abbreviations:** ASCO, American Society of Clinical Oncology; RCT, randomized controlled trial.](ott-9-4833Fig1){#f1-ott-9-4833}

![Fixed-effects model of HR (95% CI) of overall survival associated with FOLFOXIRI ± bevacizumab group compared with FOLFIRI ± bevacizumab group.\
**Notes:** Heterogeneity chi-squared =3.81 (*df* =2); *P*=0.149. *I*-squared (variation in ES attributable to heterogeneity) =47.5%. Test of ES =1: *z*=2.40; *P*=0.016.\
**Abbreviations:** HR, hazard ratio; CI, confidence interval; *df*, degrees of freedom; ES, effect size.](ott-9-4833Fig2){#f2-ott-9-4833}

![Fixed-effects model of HR (95% CI) of progression-free survival associated with FOLFOXIRI ± bevacizumab group compared with FOLFIRI ± bevacizumab group.\
**Notes:** Heterogeneity chi-squared =2.14 (*df* =1); *P*=0.144. *I*-squared (variation in ES attributable to heterogeneity) =53.3%. Test of ES =1: *z*=4.75; *P*=0.000.\
**Abbreviations:** HR, hazard ratio; CI, confidence interval; *df*, degrees of freedom; ES, effect size.](ott-9-4833Fig3){#f3-ott-9-4833}

![Random-effects model of hazard ratio (95% CI) of overall response rate associated with FOLFOXIRI ± bevacizumab group compared with FOLFIRI ± bevacizumab group.\
**Notes:** Heterogeneity chi-squared =5.00 (*df*=2); *P*=0.082. *I*-squared (variation in OR attributable to heterogeneity) =60.0%. Estimate of between-study variance Tau-squared =0.0829. Test of OR =1: *z*=3.12; *P*=0.002.\
**Abbreviations:** CI, confidence interval; OR, odds ratio; *df*, degrees of freedom.](ott-9-4833Fig4){#f4-ott-9-4833}

![Begg's funnel plots of publication bias test.\
**Notes:** Plots for (**A**) overall survival and (**B**) progression-free survival.\
**Abbreviation:** SE, standard error.](ott-9-4833Fig5){#f5-ott-9-4833}

###### 

Characteristics of the patients enrolled in the meta-analysis

  Characteristics                    Study                                                                   
  ---------------------------------- --------------- ------------- ------------- ------------- ------------- -------------
  **Median (range)**                 60.5 (29--75)   60 (29--75)   66 (25--82)   66 (39--84)   62 (27--75)   64 (21--75)
  ≥**65 years, n**                   --              --            75 (55%)      82 (56%)      --            --
  **Sex, n**                                                                                                 
   Male                              150 (59.5%)     156 (60.9%)   76 (55%)      85 (58%)      75 (61%)      69 (57%)
   Female                            102 (40.5%)     100 (39.1%)   61 (45%)      61 (42%)      47 (39%)      53 (43%)
  **ECOG performance status, n**                                                                             
   0                                 227 (90.1%)     229 (89.5%)   49 (36%)      55 (38%)      74 (60%)      74 (61%)
   1--2                              25 (9.9%)       27 (10.5%)    88 (64%)      91 (62%)      48 (40%)      48 (39%)
  **Previous adjuvant therapy, n**   32 (12.7%)      32 (12.5%)    92 (63%)      89 (65%)      29 (24%)      29 (24%)
  **Time to metastases, n**                                                                                  
   Synchronous                       197 (78.2%)     207 (80.9%)   66 (48%)      63 (43%)      --            --
   Metachronous                      55 (21.8%)      49 (19.1%)    70 (52%)      83 (57%)      --            --
  **Köhne prognostic score, n**                                                                              
   High risk                         18 (7.1%)       29 (11.3%)    37 (27%)      35 (24%)      --            --
   Intermediate risk                 111 (44.0%)     113 (44.2%)   56 (41%)      57 (39%)      --            --
   Low risk                          108 (42.9%)     105 (41.0%)   44 (32%)      54 (37%)      --            --
  **Localization, n**                                                                                        
   Colon                             --              --            100 (73%)     110 (75%)     81 (66%)      95 (78%)
   Rectum                            --              --            37 (27%)      36 (25%)      41 (34%)      27 (22%)
  **Number of metastatic sites**                                                                             
   ≤1                                59 (23.4%)      46 (18.0%)    55 (40%)      59 (40%)      65 (53%)      67 (55%)
   \>1                               193 (76.6%)     210 (82.0%)   82 (60%)      87 (60%)      57 (47%)      55 (45%)

**Note:** Data from various studies.[@b10-ott-9-4833]--[@b15-ott-9-4833]

**Abbreviation:** ECOG, Eastern Cooperative Oncology Group.

###### 

Characteristics of enrolled trials, including treatment regimens and survival data

  Author                             Country   Phase   Line   Age (years)   Number   Treatment                 Male (%)   Median OS (months)   Median PFS (months)   ORR (%)   Postchemotherapy R0 surgical resections (%)   ECOG PS   Jadad score
  ---------------------------------- --------- ------- ------ ------------- -------- ------------------------- ---------- -------------------- --------------------- --------- --------------------------------------------- --------- -------------
  Loupakis et al[@b12-ott-9-4833]    Italy     III     1st    ≥18 and ≤75   508      FOLFOXIRI + bevacizumab   59.5       31                   12.1                  65        15                                            0--2      4
                                                                                     FOLFIRI + bevacizumab     60.9       25.8                 9.7                   53        12                                            --        
  Cremolini et al[@b10-ott-9-4833]   Italy     III     1st    ≥18 and ≤75   508      FOLFOXIRI + bevacizumab   59.5       29.8                 --                    --        --                                            0--2      4
                                                                                     FOLFIRI + bevacizumab     60.9       25.8                 --                    --        --                                                      
  Souglakos et al[@b14-ott-9-4833]   Greece    III     1st    ≥18           283      FOLFOXIRI                 55         21.5                 --                    43        10                                            0--2      4
                                                                                     FOLFIRI                   58         19.5                 --                    33.6      4                                                       
  Vamvakas et al[@b15-ott-9-4833]    Greece    III     1st    ≥18           283      FOLFOXIRI                 55         21.9                 --                    43        --                                            0--2      4
                                                                                     FOLFIRI                   58         19.9                 --                    33.6      --                                                      
  Falcone et al[@b11-ott-9-4833]     Italy     III     1st    ≥18 and ≤75   244      FOLFOXIRI                 61         22.6                 9.8                   60        15                                            0--2      4
                                                                                     FOLFIRI                   57         16.7                 6.9                   34        6                                                       
  Masi et al[@b13-ott-9-4833]        Italy     III     1st    ≥18 and ≤75   244      FOLFOXIRI                 61         23.4                 9.8                   --        --                                            0--2      4
                                                                                     FOLFIRI                   57         16.7                 6.8                   --        --                                                      

**Abbreviations:** OS, overall survival; PFS, progression-free survival; ORR, overall response rate; ECOG, Eastern Cooperative Oncology Group; PS, performance status.

###### 

Most common grade 3 or 4 AEs

  Study AEs (%)         Loupakis et al[@b12-ott-9-4833]   Souglakos et al[@b14-ott-9-4833]   Falcone et al[@b11-ott-9-4833]   Total   *P*-value                       
  --------------------- --------------------------------- ---------------------------------- -------------------------------- ------- ----------- ----- ------ ------ ----------
  **Hematologic**                                                                                                                                                     
  Neutrophils           50                                20.5                               35                               28.1    50          28    46.2   24.3   0.004
  Platelets             --                                --                                 2                                4       2           1     0.1    1.3    0.665
  Anemia                --                                --                                 4                                1       3           1     1.8    0.4    0.043
  **Nonhematologic**                                                                                                                                                  
  Nausea/vomiting       7.2                               6.3                                4.6                              4.8     12.3        2.5   7.8    5      0.286
  Diarrhea              18.8                              10.6                               27.7                             10.9    20          12    21.5   10.9   \<0.0001
  Stomatitis            8.8                               4.3                                --                               --      5           3     5.6    2.9    0.04
  Febrile neutropenia   8.8                               6.3                                7                                4       5           3     7.4    5      0.115
  Asthenia              12                                9.1                                --                               --      6           3     7.4    5.2    0.173
  Neuropathy            5.2                               0                                  5.8                              0       2           0     4.8    0      0.001

**Abbreviation:** AEs, adverse events.
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